Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Validation of the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) Prognostic Classification for Targeted Therapies (TKI/mTOR Inhibitors) in Second Line After First Line Treatment With Pazopanib

Next Previous
X
Search
Trial Profile

Validation of the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) Prognostic Classification for Targeted Therapies (TKI/mTOR Inhibitors) in Second Line After First Line Treatment With Pazopanib

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 16 Feb 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pazopanib (Primary) ; Axitinib; Cabozantinib; Everolimus; Savolitinib; Sorafenib; Sunitinib; Temsirolimus
  • Indications Renal cell carcinoma
  • Focus Therapeutic Use
  • Acronyms Spazo-2

    • Most Recent Events

    • 25 Apr 2018 Status changed to completed.
    • 10 Feb 2018 Results assessing outcomes of patients treated with pazopanib as first line in mRC according to gender, presented at the 2018 Genitourinary Cancers Symposium
    • 12 Sep 2017 Status changed from recruiting to active, no longer recruiting as per results presented at the 42nd European Society for Medical Oncology Congress

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top